Research progress of phosphodiesterase 5 in heart failure
oleh: YANG Yang, ZHANG Yarong, YANG Hongqin, WANG Jing, ZHAO Hongmei
| Format: | Article |
|---|---|
| Diterbitkan: | Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2024-05-01 |
Deskripsi
Phosphodiesterase 5 (PDE5), a cyclic guanosine monophosphate (cGMP)-specific hydrolase, is targets cGMP produced by soluble guanosine cyclase (sGC) that is activated by nitric oxide (NO). It catalyzes the hydrolysis of the phosphodiester bond in cGMP and converts cGMP to the inactive 5′-GMP form. The cGMP-PKG axis dysfunction is one of the main causes of heart failure (HF) and causes cardiac remodeling. However, the clinical efficacy of PDE5 inhibitors in the treatment of heart failure is controversial. This paper summarizes the mechanism and research progress of PDE5 in heart failure in recent years, which has important significance for the clinical application of PDE5 in heart failure.